PET/MR在乳腺癌中是否有作用?
PET/MRI自2010年面世,将功能与形态学高分辨率MRI数据与PET代谢信息结合。在肿瘤领域,大量研究提示PET/MRI对全身肿瘤分期有高诊断价值;对乳腺癌,18F-FDG PET/MRI在全身分期尤其是治疗监测方面极有价值,并可能成为新辅助治疗中疗效评估及「一站式」分期工具。
要点
- 18F-FDG PET/MRI对乳腺癌全身分期及治疗监测极有价值。
- 因软组织对比高,骨等远处转移检出优于CT加骨扫描的常规分期。
- 18F-FDG PET/MRI未来可能用于新辅助治疗中或替代手术前的疗效评估。
核心结论
- 18F-FDG PET/MRI对乳腺癌全身分期尤其是治疗监测极有价值,未来可能成为新辅助治疗中或替代手术前的疗效评估手段。
研究设计与样本
- 本文为综述,围绕2010年面世的PET/MRI在乳腺癌中的应用进行讨论。
主要发现
- 同时采集PET代谢数据与MRI数据,因MRI对乳腺组织分辨率优于CT,预期对乳腺癌评估有重大影响。
- 关于乳腺18F-FDG PET/MRI在乳腺癌原发诊断中相较乳腺MRI的附加价值是否有临床影响,目前仍有争论。
- 大量研究已证明18F-FDG PET/MRI对乳腺癌全身分期尤其是治疗监测极有价值。
- 因MRI高软组织对比与功能成像及PET代谢信息,器官尤其骨内远处转移的检出优于CT加骨扫描的常规分期算法,并可显著影响治疗方案。
- 改进的影像与诊断信心使局部治疗控制能以更小侵袭性实现,而非许多患者接受乳房切除与广泛腋窝清扫。
临床怎么用
- 与常规分期检查相比辐射暴露更低,18F-FDG PET/MRI可能作为全面的「一站式」乳腺癌分期工具,一次检查完成精确局部与全身分期(含头部MRI)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PET/MRI has been available since 2010, representing the newest of the hybrid imaging modalities. It combines functional as well as morphologic high-resolution MRI data with metabolic information from PET, providing image data sets with complementary information. Especially in the field of oncology, PET/MRI is a promising imaging modality with diverse applications. Since its introduction there has already been a large quantity of studies indicating a high diagnostic value of PET/MRI for whole-body cancer staging. The simultaneous acquisition of metabolic PET and MRI data is expected to have a major impact in the assessment of breast cancer due to the superior resolution of MRI in breast tissue compared to CT. While there is an ongoing debate if the added value of breast 18F-FDG PET/MRI in the primary diagnosis of breast cancer has clinical impact compared to breast MRI, a large number of studies have proven that 18F-FDG PET/MRI is extremely valuable for whole-body breast cancer staging and especially for treatment monitoring. Besides molecular markers, distant metastases and axillary lymph node involvement are the most important predictors for overall survival and recurrence in breast cancer patients. Due to the high soft tissue contrast, functional imaging from MRI and metabolic information from PET, distant metastases in organs and in particular in the bones are detected better compared to the conventional staging algorithm with CT and bone scan and can significantly influence the therapy regime. Instead of mastectomy and extensive axillary dissection being performed in many patients, the improved imaging and diagnostic confidence also has helped that local therapy control can be achieved with reduced invasiveness. A future role of 18F-FDG PET/MRI could therefore become treatment response evaluation under neoadjuvant treatment before or instead of operative therapy. In addition to reduced radiation exposure compared to conventional staging examinations, hybrid 18F-FDG PET/MRI might serve as a comprehensive "all-in-one" breast cancer staging tool, providing precise local and whole-body staging including MRI of the head in one procedure, which save patients a diagnostic marathon.
引用
- Bruckmann NM, Morawitz J, Fendler WP, et al. A Role of PET/MR in Breast Cancer? Semin Nucl Med. 2022. PMID: 35260243. doi:10.1053/j.semnuclmed.2022.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。